# Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

> **NCT00143741** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 20 (actual)

## Conditions studied

- End-Stage Kidney Disease

## Interventions

- **DRUG:** Atorvastatin (Lipitor)

## Key facts

- **NCT ID:** NCT00143741
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2010-12
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143741, "Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00143741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*